Barrington Research Upgrades Haemonetics (HAE) to Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Haemonetics (HAE) Tops Q2 EPS by 11c; Updates on Restructuring
November 7, 2016 8:21 AM ESTHaemonetics (NYSE: HAE) reported Q2 EPS of $0.46, $0.11 better than the analyst estimate of $0.35. Revenue for the quarter came in at $220.25 million versus the consensus estimate of $210.72 million.
RESTRUCTURING AND TURNAROUND EXPENSES AND DEAL AMORTIZATION
The Company announced and has been implementing a turnaround plan to... More
